Insulet Corporation $PODD Shares Sold by Primecap Management Co. CA

Primecap Management Co. CA cut its stake in Insulet Corporation (NASDAQ:PODD) by 55.6% in the second quarter, Holdings Channel.com reports. The firm owned 188,721 shares of the medical instruments supplier’s stock after selling 236,297 shares during the quarter. Primecap Management Co. CA’s holdings in Insulet were worth $59,292,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. American Century Companies Inc. grew its holdings in Insulet by 34.8% in the 1st quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock valued at $302,686,000 after buying an additional 297,734 shares in the last quarter. Nuveen LLC purchased a new stake in shares of Insulet in the first quarter valued at about $74,163,000. Kayne Anderson Rudnick Investment Management LLC increased its position in Insulet by 1,316.5% during the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 193,511 shares of the medical instruments supplier’s stock worth $50,818,000 after purchasing an additional 179,850 shares during the last quarter. Vanguard Group Inc. increased its position in Insulet by 2.1% during the first quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier’s stock worth $2,276,553,000 after purchasing an additional 178,976 shares during the last quarter. Finally, AustralianSuper Pty Ltd raised its stake in Insulet by 487.5% during the second quarter. AustralianSuper Pty Ltd now owns 205,168 shares of the medical instruments supplier’s stock worth $64,460,000 after purchasing an additional 170,247 shares during the period.

Insulet Stock Up 3.9%

NASDAQ:PODD opened at $346.36 on Thursday. Insulet Corporation has a 52 week low of $230.05 and a 52 week high of $353.50. The stock’s fifty day moving average is $322.93 and its two-hundred day moving average is $314.19. The stock has a market capitalization of $24.37 billion, a price-to-earnings ratio of 105.28, a price-to-earnings-growth ratio of 2.64 and a beta of 1.39. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. The company had revenue of $521.70 million for the quarter, compared to analyst estimates of $678.70 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business’s revenue for the quarter was up 29.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.08 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Research analysts anticipate that Insulet Corporation will post 3.92 EPS for the current year.

Insider Buying and Selling at Insulet

In other Insulet news, SVP Laetitia Cousin sold 797 shares of the company’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the sale, the senior vice president owned 3,890 shares in the company, valued at $1,356,870.90. This represents a 17.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Prem Singh sold 687 shares of the stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the sale, the senior vice president directly owned 3,456 shares in the company, valued at $1,200,925.44. This represents a 16.58% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 0.39% of the company’s stock.

Analyst Upgrades and Downgrades

PODD has been the subject of several analyst reports. Wall Street Zen raised shares of Insulet from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Wells Fargo & Company upped their price objective on Insulet from $350.00 to $360.00 and gave the company an “overweight” rating in a report on Friday, November 7th. JPMorgan Chase & Co. raised their target price on Insulet from $340.00 to $415.00 and gave the stock an “overweight” rating in a research note on Friday, September 12th. Rothschild & Co Redburn upped their price target on Insulet from $350.00 to $370.00 and gave the company a “buy” rating in a research note on Friday, October 3rd. Finally, Zacks Research upgraded Insulet from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 14th. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $376.35.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.